Submit Manuscript  

Article Details


Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases

[ Vol. 15 , Issue. 7 ]

Author(s):

Marcos L. Aranda, María Florencia González Fleitas, Hernán Dieguez, Agustina Iaquinandi, Pablo H. Sande, Damián Dorfman and Ruth E. Rosenstein   Pages 951 - 962 ( 12 )

Abstract:


Background: Uveitis and optic neuritis are prevalent ocular inflammatory diseases, and highly damaging ocular conditions. Both diseases are currently treated with corticosteroids, but they do not have adequate efficacy and are often associated with severe side effects. Thus, uveitis and optic neuritis remain a challenging field to ophthalmologists and a significant public health concern.

Objective: This review summarizes findings showing the benefits of a treatment with melatonin in experimental models of these inflammatory ocular diseases.

Results: Oxidative and nitrosative damage, tumor necrosis factor, and prostaglandin production have been involved in the pathogeny of uveitis and optic neuritis. Melatonin is an efficient antioxidant and antinitridergic, and has the ability to reduce prostaglandin and tumor necrosis factor levels both in the retina and optic nerve. Moreover, melatonin not only prevents functional and structural consequences of experimental uveitis and optic neuritis, but it is also capable of suppressing the actively ongoing ocular inflammatory response.

Conclusions: Since melatonin protects ocular tissues against inflammation, it could be a potentially useful anti-inflammatory therapy in ophthalmology.

Keywords:

Melatonin, uveitis, optic neuritis, ocular inflammation, oxidative damage, nitrosative damage.

Affiliation:

Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Department of Human Biochemistry, School of Medicine, CEFyBO, University of Buenos Aires, CONICET, Paraguay 2155, 5th Floor, (1121), Buenos Aires

Graphical Abstract:



Read Full-Text article